
|Articles|December 9, 2014
Sorafenib Demonstrates Activity in AML
Author(s)Christoph Röllig, MD
In this video from the 2014 ASH Annual Meeting, Dr. Röllig discusses the results of the SORAML trial that tested sorafenib in patients with acute myeloid leukemia.
Advertisement
At the 2014 American Society of Hematology Annual Meeting, Christoph Röllig, MD, of University Hospital Dresden, Germany, discusses the results of the SORAML trial that tested sorafenib compared with placebo as add-on to standard induction and consolidation treatment in patients with acute myeloid leukemia (AML) aged 18 to 60 years.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
2
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
3
Zenocutuzumab Earns FDA National Priority Voucher in Cholangiocarcinoma
4
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
5



















































